Allergy Immunotherapy Market By Allergen Type, By Age Group, By Type Of Immunotherapy (Subcutaneous Immunotherapy, Sublingual Immunotherapy ), By Distribution Channel, & Region For 2024-2031

Allergy Immunotherapy Market Valuation - 2024-2031

Allergy Immunotherapy Market size was valued at USD 2.08 Billion in 2023 and is projected to grow USD 3.87 Billion by 2031, exhibiting a CAGR of 8.10% during the forecast period. The Allergy Immunotherapy Market is expanding due to the increasing frequency of allergic illnesses such as allergic rhinitis, asthma, and food allergies. As more people seek effective, long-term treatment alternatives, the preference for immunotherapy over standard drugs is becoming clear. This is especially true for people who want to relieve their symptoms without having to use antihistamines or corticosteroids all the time.

Furthermore, advances in allergen-specific immunotherapy products and administration modalities such as sublingual tablets and injections, are improving patient access and adherence. Increasing awareness of immunotherapy's benefits combined with recommendations from healthcare experts is driving market expansion. With an emphasis on personalized medication, the allergy immunotherapy industry is expected to grow significantly in the coming years.

Allergy Immunotherapy Market: Definition/ Overview

Allergy immunotherapy is a treatment that aims to lower sensitivity to allergens resulting in long-term relief from allergy symptoms. It entails gradually administering increasing doses of certain allergens, either via subcutaneous injections (allergen immunotherapy) or sublingual tablets/drops. This mechanism helps the immune system develop tolerance to allergens reducing the severity of allergic reactions.

It is used to treat allergy diseases by progressively reducing the immune system's sensitivity to specific allergens. It entails the introduction of allergens in controlled dosages by injections (subcutaneous immunotherapy) or sublingual pills. This approach reduces the severity of allergic reactions over time and can provide long-term relief, even after therapy is completed. Allergy immunotherapy is beneficial for illnesses such as allergic rhinitis, asthma, and specific food allergies enhancing patients' quality of life and lowering drug use.

The future of allergy immunotherapy will center on personalized treatment techniques that use genetic and biomarker data to adapt medicines to specific patients. Innovative drug delivery systems, such as microneedles and wearable devices are expected to improve patient compliance and comfort. Furthermore, studies on new allergen sources and combination medicines will expand therapy choices.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

How has the Rising Awareness among Healthcare Professionals and Patients Impacted the Growth of the Allergy Immunotherapy Market?

Rising awareness among healthcare professionals and patients has accelerated the growth of the Allergy Immunotherapy Market. As more healthcare practitioners recognize the long-term benefits of immunotherapy over traditional allergy medications, they are more likely to promote it as a viable allergy management option. This shift in clinical practice, fuelled by improved education on the efficacy and safety of immunotherapy has resulted in increased acceptance of therapies such as Subcutaneous Immunotherapy (SCIT) and Sublingual Immunotherapy (SLIT), hence contributing to market growth.

From the patient's perspective, a rising understanding of allergy immunotherapy's ability to provide long-term comfort, rather than just temporary symptom relief has resulted in increased demand for these therapies. As patients become more aware of their alternatives, they are more likely to choose personalized, long-term allergy treatments. This rising demand combined with professional endorsements from healthcare practitioners has pushed the adoption of immunotherapy propelling total market expansion.

How Does the High Cost of Treatment Act as a Restraint in the Allergy Immunotherapy Market?

The high cost of treatment is a significant barrier in the Allergy Immunotherapy Market limiting patient access to care. Allergy immunotherapy, particularly Subcutaneous Immunotherapy (SCIT) needs several sessions over several years which can be costly for patients. In many areas, insurance coverage for such therapies may be limited or absent requiring patients to pay out of cash. Even though the therapy provides long-term relief for chronic allergy problems, many people are put off by the cost.

Furthermore, the high initial and recurring costs associated with immunotherapy limit its accessibility, particularly in low-income regions or nations with inadequate healthcare resources. Allocating resources for extensive immunotherapy programs may be impractical for healthcare systems with limited finances, further restricting market expansion. As a result, despite the increasing incidence of allergies and the established efficacy of immunotherapy, cost remains a significant barrier to the wider use of these treatments.

Category-Wise Acumens

How Does the Method of Allergen Exposure in SCIT Contribute to the Long-Term Efficacy of Treatment for Allergic Diseases?

Subcutaneous Immunotherapy (SCIT) dominates the Allergy Immunotherapy Market due to its long-standing efficacy and comprehensive strategy. SCIT includes injecting allergen extracts directly under the skin allowing for controlled exposure and eventual desensitization of the immune system to specific allergens. This approach has been widely researched and shown helpful for a variety of allergens, notably pollen, dust mites, and animal dander making it a popular choice among both patients and healthcare providers looking for long-term relief.

Furthermore, SCIT provides a well-defined treatment regimen with established protocols resulting in predictable dose and response. The inclusion of multiple allergens in SCIT formulations allows for more personalized therapy options for patients which improves compliance and satisfaction. While sublingual immunotherapy (SLIT) is gaining popularity due to its simplicity of administration, SCIT remains dominant due to its proven track record, strong clinical data, and allergists' preference for its comprehensive approach to addressing allergic diseases.

How Does the Preparation of Personalized Immunotherapy Regimens in Hospital Pharmacies Affect Patient Adherence to Treatment Plans?

Hospital pharmacies dominate the allergy immunotherapy industry because they have access to a wide choice of specialized drugs and treatment alternatives. These pharmacies are ready to prepare and distribute personalized immunotherapy regimens such as allergy injections and sublingual pills, based on patient needs. The presence of allergists and immunologists in hospital settings promotes teamwork, resulting in better patient care and monitoring throughout the therapy process. This integrated strategy guarantees that patients receive timely and effective medicines which leads to better outcomes.

Furthermore, hospital pharmacies benefit from established partnerships with pharmaceutical producers allowing them to obtain the most recent immunotherapy medicines and updates on treatment methods. As hospitals implement multidisciplinary care models, coordination among chemists, healthcare professionals, and patients improves. This comprehensive strategy not only improves patient adherence to medication but also creates a supportive atmosphere for continued education and follow-up reinforcing hospital pharmacies' role in the Allergy Immunotherapy Market.

Country/Region-wise Acumens

How do Reimbursement Policies Influence Patient Access to Allergy Immunotherapy in the North American Region?

North America dominates the Allergy Immunotherapy Market, owing to the increasing prevalence of allergic illnesses like allergic rhinitis and asthma which drives demand for better treatment alternatives. The region benefits from excellent healthcare facilities, extensive research programs, and a thriving pharmaceutical sector. Major corporations are significantly investing in novel medicines such as subcutaneous and sublingual immunotherapy, to meet the rising patient population. Furthermore, as healthcare practitioners and patients become more aware of allergic disorders, acceptance and usage of immunotherapy treatments have increased.

Furthermore, supporting regulatory frameworks and favorable reimbursement policies in the United States promote market expansion. The Food and Drug Administration (FDA) has approved several immunotherapy medicines, increasing their market penetration. North American healthcare systems prioritize personalized medicine and patient-centered approaches which encourages the use of allergy immunotherapy. As a result, the region is well-positioned to sustain its market leadership opening the path for ongoing breakthroughs in treatment techniques.

How are Changing Lifestyles and Urbanization Impacting the Prevalence of Asthma and Allergic Rhinitis in the Asia-Pacific Region?

Asia Pacific is the fastest-growing region in the Allergy Immunotherapy Market owing to rising allergy incidence, increased healthcare awareness, and considerable investment in R&D. Urbanisation and changing lifestyles have contributed to an increase in allergy disorders such as asthma and allergic rhinitis creating a larger demand for effective treatments. As more people become aware of the benefits of immunotherapy, healthcare providers are more likely to recommend it resulting in increased market growth.

Furthermore, supportive government initiatives and partnerships with pharmaceutical companies improve access to allergy treatments and advances. The region's increasing middle class is pushing up healthcare spending allowing for the adoption of modern therapeutic choices. Furthermore, the expansion of healthcare infrastructure and the growing number of allergists and immunologists in countries such as China and India are key drivers of market growth. Overall, the combination of increased allergies and greater healthcare access has positioned Asia Pacific as a market leader in allergy immunotherapy.

Competitive Landscape

The Allergy Immunotherapy Market is a dynamic and competitive space characterized by diverse players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support. The organizations focus on innovating their product line to serve the vast population in diverse regions.

Some of the prominent players operating in the Allergy Immunotherapy Market include:

ALK-Abello A/S, Stallergenes Greer plc, Allergy Therapeutics plc, Merck & Co., Inc. (known as MSD outside of the United States and Canada), Aimmune Therapeutics, Inc., DBV Technologies SA, HAL Allergy Group, Biomay AG, Circassia Pharmaceuticals plc, Immunomic Therapeutics, Inc., Anergis, ASIT Biotech, and Adamis Pharmaceuticals Corporation.

Latest Developments

In January 2024, Inimmune Corporation (Inimmune) and Intrommune Therapeutics, Inc. (Intrommune), two clinical-stage immunotherapeutic companies, announced a collaboration to develop a novel oral mucosal allergy immunotherapy for treating peanut allergy.

In October 2023, ALK reported the successful completion of Itulatek's phase 3 trial for treating allergy rhinoconjunctivitis caused by tree pollen.